Saatchi N.Y. Rebounds

Lands $50 Mil. in Tasks From Glaxo, P&G
NEW YORK — Still smarting from the loss of its $100 million Delta Air Lines advertising account, Saatchi & Saatchi last week captured nearly $50 million in new assignments from Procter & Gamble and drug maker Glaxo Wellcome.
For Glaxo, Saatchi here will handle creative duties on the launch of Rilenza, a prescription drug designed to lessen the severity of flu. The shop landed the business after a review with undisclosed others, sources said. Billings were estimated at $30-35 million.
Rilenza is administered via an inhaler and will compete with another fledgling brand known as Tamiflu (from Roche Holding). Unlike Tamiflu, however, Rilenza has already been approved by the U.S. Food and Drug Administration.
Jennifer Laing, Saatchi’s North American CEO, confirmed the win, but referred queries to the Research Triangle, N.C.-based client, which did not return calls. The Media Edge here handles Glaxo’s media duties.
From an existing client, P&G, Saatchi added the $15 million account of Iams and Eukanuba, which joined the consumer giant’s portfolio with its August buyout of The Iams Co. Doner in Southfield, Mich., had split with Iams after 12 years in June.
“It’s disappointing to lose a valued client such as Delta, but very satisfying to move on so quickly with business from two world-class companies,” Laing said. As for feelings in New York, where a “Welcome Glaxo Wellcome” sign hung last week: “We’re feeling upbeat, optimistic and very busy.”